Increased galectin-7 expression in B16F1 primary tumors and lung metastases.

<p>Primary tumors were collected at necropsy 18 days after the subcutaneous injection of B16F1 cells (5×10⁴ cells) in C57BL/6 (WT) and galectin-7-deficient mice (KOG7). (A) RT-PCR analysis of galectin-7 mRNA expression in two B16F1 primary tumors from WT and KOG7 mice in comparison with the B16F1 cell line. Actin was used as a loading and specificity control. B) Immunohistochemistry for galectin-7 in normal skin (i, ii) and B16F1 primary tumors (iii, iv) in WT and KOG7 mice. These galectin-7-positive structures located in the suprabasal epidermis have been reported before and likely represent suprabasal keratinocytes, which are known to express galectin-7 constitutively <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0063307#pone.0063307-Magnaldo1" target="_blank">[13]</a>. Control stained without HRP and in absence of Abs did not show any detectable staining in both wt and KOG7 mice. C) Immunohistochemistry for galectin-7 in a lung collected 20 days post-injection from one KOG7 mouse injected intravenously via the tail vein with B16F1 cells (2×10⁵ cells) in comparison with a normal lung. Scale bars in all immunohistochemistry images represent 600 µM.